Oct 29, 4:09 PM ET
Exelixis, Inc. reported its third quarter 2026 financial results, showing an increase in total revenues to $658.7 million compared to $597.8 million for the same period in 2025. GAAP net income rose to $218.1 million, or $0.85 per diluted share, driven by higher net product sales from the cabozantinib franchise.
- Total revenues for the quarter ended September 30, 2026, were $658.7 million, up from $597.8 million in the third quarter of 2025.
- GAAP net income for the third quarter of 2026 was $218.1 million, or $0.85 per diluted share.
- Cabozantinib franchise U.S. net product revenues reached $604.9 million for the quarter.
- Exelixis updated its full-year 2026 financial guidance, including total revenues projected between $2.500 billion and $2.550 billion.
Read the filing on SEC.gov ↗
Aug 5, 4:09 PM ET
Exelixis reported second quarter 2026 total revenues of $628.7 million, up from $568.3 million a year earlier, and GAAP diluted EPS of $0.82, up from $0.65. However, the company lowered its full-year 2026 total revenue guidance to $2.500 billion-$2.550 billion from $2.525 billion-$2.625 billion, and the guidance excludes any revenue from a potential launch of zanzalintinib, which the FDA is reviewing with a December 3, 2026 target action date.
- Q2 2026 total revenues were $628.7 million vs. $568.3 million in Q2 2025; net product revenues were $573.0 million vs. $520.0 million.
- GAAP diluted EPS was $0.82 vs. $0.65 a year earlier; non-GAAP diluted EPS was $0.91 vs. $0.75.
- 2026 total revenue guidance was cut to $2.500 billion-$2.550 billion from $2.525 billion-$2.625 billion; net product revenue guidance was cut to $2.300 billion-$2.350 billion from $2.325 billion-$2.425 billion.
- Exelixis repurchased $311.6 million of its stock in Q2 2026 and began buybacks under a new $750 million authorization approved in May 2026.
Read the filing on SEC.gov ↗
May 29, 4:05 PM ET
At its May 26, 2026 annual meeting, Exelixis stockholders approved an amended and restated 2017 Equity Incentive Plan, which took effect immediately, and re-elected 11 directors to serve until the 2027 annual meeting. Stockholders also ratified Ernst & Young LLP as auditor and approved the advisory say-on-pay proposal. The votes are routine governance matters that set the terms of equity awards and board composition.
- Stockholders approved the 2017 Equity Incentive Plan amendment and restatement on May 26, 2026, effective immediately upon approval.
- Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending January 1, 2027, with 222,343,120 votes for.
- Say-on-pay was approved with 163,104,135 votes for and 43,156,553 against.
- Maria C. Freire, Ph.D. received 180,367,648 votes for and 26,067,310 against, the largest share of opposition among the 11 directors.
Read the filing on SEC.gov ↗
May 5, 4:07 PM ET
Exelixis reported first-quarter 2026 total revenues of $610.8 million, up from $555.4 million a year earlier, and GAAP diluted EPS of $0.79, up from $0.55. The company maintained its 2026 financial guidance and said the zanzalintinib NDA for previously treated metastatic colorectal cancer is under FDA review with a December 3, 2026 target action date. The Board also authorized up to an additional $750 million in stock repurchases through December 31, 2027.
- Total revenues were $610.8 million versus $555.4 million; net product revenues were $555.0 million versus $513.3 million.
- GAAP diluted EPS was $0.79 versus $0.55; non-GAAP diluted EPS was $0.87 versus $0.62.
- 2026 guidance was maintained, with total revenues of $2.525 billion to $2.625 billion.
- The new $750 million repurchase program runs through December 31, 2027; the October 2025 program is expected to be completed in May 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.